Amundi 13F: Cuts Abbott Laboratories (ABT) Stake by $71M
Amundi reduced its holdings in Abbott Laboratories by 9.5% during the period, according to a recent SEC filing.
Reviewed by automated data checks against the source filing. How we make and check alerts
Amundi sold 778,681 shares from its stake in Abbott Laboratories ($ABT), a 9.51% decrease, according to a 13F filing with the SEC dated May 18, 2026. It reported 7,406,961 shares worth $673.29 million at the end of the quarter.
Since the filing, $ABT is down 1.4% after 1 week, up 0.7% after 1 month and up 20.9% to date (from the $86.75 close on May 18, 2026).
ABT
Abbott Laboratories
Key Points
- Amundi trimmed its position in Abbott Laboratories by selling 778,681 shares, leaving it with 7,406,961 shares valued at roughly $673.3 million.
- Abbott Laboratories shares trade around $90.90, well below their 52-week high of $132.03 and under key moving averages.
- Analyst sentiment remains generally positive with firms like TD Cowen maintaining a Buy rating and a $135 price target.
Get $ABT trade alerts by text
We text you when insiders, Congress or big funds trade $ABT. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Abbott Laboratories alert may contain errors. Disclosures
Amundi Trims Position in Abbott Laboratories
Amundi reduced its investment in Abbott Laboratories (NYSE: ABT) during the period, cutting its stake by 9.5%, according to its latest Form 13F filing with the SEC. The fund sold 778,681 shares, bringing its ending position to 7,406,961 shares. Based on the reporting period, that remaining stake carried a value of approximately $673.3 million. Institutional filings are backward-looking and show holdings as of that specific date, meaning they might not reflect the fund's current share count today.
Abbott Laboratories Stock Sits Below Recent Moving Averages
Abbott Laboratories shares trade around $90.90, sitting closer to the bottom of their 52-week range of $81.97 to $132.03. The stock sits below its 50-day moving average of $105.93 and its 200-day moving average of $102.91. The health care giant carries a market capitalization of roughly $181.1 billion and a forward P/E ratio of 17.26, while its trailing P/E sits at 33.77.
Recent Earnings Highlight Steady Health Care Demand
Abbott Laboratories generated $46.58 billion in revenue over the trailing twelve periods, marking a 13.0% revenue growth rate. The company posted an earnings per share of $3.10 alongside a net margin of 11.6% and a return on equity of 10.6%. Its next quarterly earnings report is scheduled for October 21, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
8 target cuts vs 0 raises.
-
EPS & revenue
EPS met estimates. Revenue beat estimates by 0.5%.
-
Profit surprise
EBITDA missed by 43 percent. Operating income missed by 19 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
8 target cuts.
-
Earnings quality
Gross margin up 3.7 points. Positive free cash flow.
Earnings Call Summary
Abbott completed its $2.4 billion acquisition of Exact Sciences on March 23 and is integrating the cancer diagnostics business into its portfolio. First quarter results came in slightly ahead, with sales of $11.2 billion, up 3.7 percent on a comparable basis, though the respiratory season was weaker than expected. The company is seeing early signs of volume recovery in Nutrition after price increases, expects Core Lab Diagnostics to accelerate, and is launching new cardiac devices like the Volt pulsed field ablation catheter and TactiFlex Duo. Management remains confident in second half acceleration but is being cautious on near term market conditions.
Guidance Abbott cut full year earnings guidance from $5.68 to $5.48 per share, reflecting $0.20 of dilution from the Exact Sciences acquisition. The company guided full year revenue growth of 6.5 percent to 7.5 percent on a comparable basis including Exact Sciences. For the second quarter, Abbott expects earnings of $1.25 to $1.31 per share. Management said they are being conservative on respiratory season assumptions and expect acceleration in the second half driven by Nutrition recovery, Core Lab Diagnostics growth, and Exact Sciences integration.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend Yield Offers Income for Shareholders
Abbott Laboratories pays an annual dividend yielding 2.41%, supported by a dividend payout ratio of 78.7%. The payout distributes a portion of corporate earnings back to investors while leaving room to fund ongoing operations and research in medical devices and pharmaceuticals.
Analysts Set New Price Targets
Wall Street firms continue to keep favorable outlooks on the stock despite recent market pullbacks. On October 16, 2026, TD Cowen maintained its Buy rating with a $135.00 price target. Earlier in October, Barclays initiated coverage with an Overweight rating and a $120.00 price target, while Rothschild & Co upgraded the stock to a Buy with a $127.00 price target on October 2, 2026.
Inside Abbott Laboratories' Medical Business
Headquartered in Abbott Park, Illinois, Abbott Laboratories discovers, manufactures, and sells a wide array of health care products worldwide. The company operates across four main segments covering medical devices, diagnostic products, nutritional goods, and established pharmaceuticals. With a global workforce of 122,000 employees, the firm develops everything from diabetes monitoring systems and cardiovascular devices to rapid diagnostic tests and infant formulas.
What to Watch Next for Abbott Laboratories
Investors will look toward the company's upcoming earnings release on October 21, 2026, for fresh updates on revenue and device sales. Future 13F filings will also reveal whether other large institutional managers followed Amundi's lead in adjusting their stakes. As always, these historical snapshots provide a look at past portfolio choices rather than advice on current trades.
Related Filing Alerts
Source: Amundi's 13F filing on $ABT (May 18, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Amundi 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts